Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by reziak72on Oct 20, 2020 12:54am
406 Views
Post# 31746488

Everyone

Everyone

needs to chill the fcuk out and re-re-read this. Not sure how you can take this as a negative...

The final amount raised in the Offering will determine the speed at which each of the Company’s business milestones may be achieved. Assuming the completion of the Maximum Offering, the Company intends to: (i) pay the salaries and benefits for current employees for one year (approximately $3,330,000 in costs, $2,250,000 of which is expected to be paid from existing cash on hand), (ii) hire twenty-four (24) additional full-time employees to enhance lab testing capabilities and sales (instead of twelve (12) full-time employees under the Minimum Offering scenario) to enhance lab testing capabilities and sales (approximately $2,670,000 in costs, $nil of which is expected to be paid from existing cash on hand); (iii) purchase equipment, testing reagents and consumable materials for COVID-19 testing and Aristotle® development and sale (approximately $1,900,000 in costs, $nil of which is expected to be paid from existing cash on hand); (iv) pay for corporate marketing expenses for current products including COVID-19 and Aristotle® testing (approximately $3,000,000 in costs, $nil of which is expected to be paid from existing cash on hand); and (v) expand the Richmond Laboratory by approximately 5,000 square feet (approximately $180,000 in costs, $nil of which is expected to be paid from existing cash on hand). In addition to these testing capability enhancements, the Company intends to use a portion of the net proceeds of the Offering for working capital and general corporate purposes..

Kuudos to whomever I grabbed this from

Bullboard Posts